immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma

Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive form of brain cancer

(PresseBox) ( Tübingen, )
immatics biotechnologies GmbH, a clinicalstage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics' therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.

Under the terms of the agreement, CCR will sponsor and conduct a phase I trial of IMA950 which will be carried out at the National Institute of Health's (NIH's) Facility in Bethesda, Maryland, U.S. The phase I trial will evaluate IMA950 in stable or recurrencefree glioblastoma patients following standard radiochemotherapy with temozolomide.

The principal investigator of the study is Dr. Howard Fine, Chief of the Neuro-Oncology Branch at the National Cancer Institute. immatics will collaborate with CCR and will also be responsible for drug supply for the study as well as undertaking immunomonitoring of the treated patients.

This collaboration follows an agreement immatics signed with Cancer Research UK in February for the clinical development of IMA950 in glioblastoma. The Cancer Research UK sponsored study will treat newly diagnosed patients with IMA950 in combination with radiochemotherapy while this study at the NCI will treat patients after successful radiochemotherapy with standalone IMA950. The different protocols for these two studies should mean that they provide complementary data reflecting the different clinical situations experienced by glioblastoma patients.

Paul Higham, CEO of immatics said: "We are delighted to be collaborating with such a prestigious organization as the National Cancer Institute to help us to develop our third therapeutic vaccine, IMA950. Our ability to secure two such highly regarded collaborators to advance IMA950 into the clinic demonstrates the significant interest in immatics' novel therapeutic vaccines and the need for a much improved treatment option for glioblastoma. We very much look forward to working with the NCI to further develop IMA950 and to evaluate how it may be of benefit in this devastating disease."

About IMA950

IMA950 is a therapeutic cancer vaccine generated through immatics' proprietary XPRESIDENT(TM) technology. It consists of 11 tumorassociated peptides (TUMAPs) which the immatics platform selected on the basis of their natural presentation by tumor tissue, overexpression in tumor vs. healthy tissue, immunogenicity and their relevance to tumor function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumor peptides is at the core of all immatics' clinical programs.

About NCI

The US National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI is the Federal Government's principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.